Excellergy Deal History & Licensing Activity
Excellergy is a life sciences. Over the past three years, Excellergy has been involved in 2 licensing and acquisition transactions, with a primary focus on Antibodies (4 deals).
Deals (12mo)
0
Active Trials
0
Top Modality
Antibodies
Focus Area
Mega Deals
Excellergy Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Excellergy in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Exl-111 | Novartis | Antibodies | Preclinical | acquisition | Apr 2026 |
| Exl-111 | Novartis | Antibodies | Phase 1 | acquisition | Mar 2026 |
Excellergy Pipeline Focus
Therapeutic areas and modalities where Excellergy is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Excellergy's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Excellergy Licensing & Deal Activity
Excellergy is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Excellergy ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Excellergy include Mega Deals (2 deals and trials), and Immunology (2 deals and trials). In terms of modality, Excellergy has shown particular interest in antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Excellergy and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Excellergy's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.